Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 22, 2026
DataAggregated Company Financials
Companies146
  • 7D1.7%
  • 3M6.5%
  • 1Y11.0%
  • YTD4.3%

Over the last 7 days, the Healthcare industry has risen 4.3%, driven by gains from Sectra of 8.1%. In the same time, BioArctic was down 7.0%. In the last 12 months, the industry was up 11%. Looking forward, earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 22 Apr 2026SEK 609.4bSEK 227.7b-SEK 2,565,427,837.2734.9x-237.5x2.7x
Fri, 20 Mar 2026SEK 539.9bSEK 228.8b-SEK 2,897,162,989.5330.1x-186.3x2.4x
Sun, 15 Feb 2026SEK 565.4bSEK 230.7b-SEK 1,735,172,894.8930.8x-325.8x2.5x
Tue, 13 Jan 2026SEK 591.8bSEK 230.2bSEK 3.7b41x161.3x2.6x
Thu, 11 Dec 2025SEK 584.0bSEK 230.5bSEK 3.5b41.4x164.8x2.5x
Sat, 08 Nov 2025SEK 587.5bSEK 229.8bSEK 2.9b44.7x202.5x2.6x
Mon, 06 Oct 2025SEK 614.2bSEK 227.1bSEK 6.6b43.2x93x2.7x
Wed, 03 Sep 2025SEK 610.1bSEK 227.2bSEK 6.6b44.6x92.6x2.7x
Fri, 01 Aug 2025SEK 626.0bSEK 226.8bSEK 6.5b51.6x95.8x2.8x
Sun, 29 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Tue, 27 May 2025SEK 597.5bSEK 226.0bSEK 6.6b38.1x90.8x2.6x
Thu, 24 Apr 2025SEK 563.8bSEK 222.2bSEK 4.9b38.5x115.2x2.5x
Sat, 22 Mar 2025SEK 556.7bSEK 206.2bSEK 5.0b36.7x110.3x2.7x
Mon, 17 Feb 2025SEK 594.9bSEK 206.5bSEK 2.5b41.7x237.8x2.9x
Wed, 15 Jan 2025SEK 572.2bSEK 201.6b-SEK 2,648,231,775.5139x-216.1x2.8x
Fri, 13 Dec 2024SEK 572.6bSEK 202.8b-SEK 2,465,110,847.0638.3x-232.3x2.8x
Sun, 10 Nov 2024SEK 528.0bSEK 200.2b-SEK 2,454,224,230.9538.6x-215.2x2.6x
Tue, 08 Oct 2024SEK 603.4bSEK 200.1b-SEK 2,782,864,383.9938.7x-216.8x3x
Thu, 05 Sep 2024SEK 606.1bSEK 200.1b-SEK 2,809,341,520.0139x-215.7x3x
Sat, 03 Aug 2024SEK 569.5bSEK 199.6b-SEK 2,762,712,499.7440.4x-206.1x2.9x
Mon, 01 Jul 2024SEK 562.0bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Wed, 29 May 2024SEK 556.4bSEK 195.9b-SEK 2,792,392,543.2436.3x-199.2x2.8x
Fri, 26 Apr 2024SEK 547.0bSEK 195.2b-SEK 3,609,418,549.8644.5x-151.6x2.8x
Sun, 24 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,668,825,382.9843.3x-141.7x2.7x
Tue, 20 Feb 2024SEK 517.5bSEK 191.7b-SEK 4,105,248,032.6349x-126.1x2.7x
Thu, 18 Jan 2024SEK 546.4bSEK 191.7b-SEK 968,025,477.0047.7x-564.5x2.9x
Sat, 16 Dec 2023SEK 543.4bSEK 191.4b-SEK 942,084,132.0050.3x-576.8x2.8x
Mon, 13 Nov 2023SEK 470.7bSEK 190.3b-SEK 1,054,239,686.0049.4x-446.5x2.5x
Wed, 11 Oct 2023SEK 450.7bSEK 184.9b-SEK 2,029,425,074.0034.2x-222.1x2.4x
Fri, 08 Sep 2023SEK 454.7bSEK 185.7b-SEK 2,025,575,303.0036.2x-224.5x2.4x
Sun, 06 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,034,178,130.0039.9x-457.5x2.6x
Tue, 04 Jul 2023SEK 474.9bSEK 179.3b-SEK 795,617,474.0044.8x-596.9x2.6x
Thu, 01 Jun 2023SEK 506.4bSEK 178.8b-SEK 545,224,135.0042.7x-928.7x2.8x
Sat, 29 Apr 2023SEK 518.2bSEK 175.8b-SEK 792,830,499.0035.3x-653.6x2.9x
Price to Earnings Ratio

-653.6x


Total Market Cap: SEK 518.2bTotal Earnings: -SEK 792,830,499.00Total Revenue: SEK 175.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -161.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.01%
Healthcare1.65%
Healthtech7.50%
Life Sciences4.05%
Pharma3.04%
Healthcare Services2.95%
Medical Equipment1.27%
Biotech-0.60%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 20.0%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 268.808.1%
+SEK 3.9b		-1.0%PE96.4x
ASKER Asker Healthcare GroupSEK 80.758.4%
+SEK 2.4b		6.3%PE62.9x
CAMX CamurusSEK 557.004.4%
+SEK 1.4b		-0.9%PE45.2x
ALIF B AddLifeSEK 168.005.6%
+SEK 1.1b		9.6%PE36.6x
VITR VitrolifeSEK 110.106.0%
+SEK 839.6m		-27.8%PS4.3x

Latest News

ELIC
SEK 3.42
Elicera Therapeutics
7D
-39.4%
1Y
0.9%
EGTX
SEK 5.25
Egetis Therapeutics
7D
-9.0%
1Y
50.4%
ASKER
SEK 80.75
Asker Healthcare Group
7D
8.4%
1Y
6.3%
SECT B
SEK 268.80
Sectra
7D
8.1%
1Y
-1.0%
VIMIAN
SEK 29.95
Vimian Group
7D
-2.9%
1Y
-15.4%

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.
HNSA
SEK 27.68
Hansa Biopharma
7D
-7.5%
1Y
23.0%

HNSA: Kidney Transplant FDA Review Will Drive Upside Despite Recent Model Reset

Analysts have reduced their SEK price target on Hansa Biopharma by SEK 8, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent commentary around the revised SEK price target highlights how analysts are recalibrating their models rather than shifting their overall view of Hansa Biopharma as a whole.
GETI B
SEK 198.20
Getinge
7D
0.9%
1Y
8.0%
CAMX
SEK 557.00
Camurus
7D
4.4%
1Y
-0.9%

CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside

Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.
VITR
SEK 110.10
Vitrolife
7D
6.0%
1Y
-27.8%

VITR: Governance Amendments And Steady Assumptions Will Support Future Upside

Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.
ATT
SEK 106.80
Attendo
7D
-1.6%
1Y
73.1%

ATT: Proposed 2025 Dividend And Governance Changes Will Support Steady Outlook

Analysts have kept Attendo's fair value estimate unchanged at SEK110, with only minor tweaks to inputs such as the discount rate and future P/E assumptions guiding this level view. What's in the News The Board has proposed an amendment to Attendo AB (publ)'s Articles of Association, signaling upcoming changes to the company's formal governance framework (Key Developments).
ALIF B
SEK 168.00
AddLife
7D
5.6%
1Y
9.6%

ALIF B: Higher Margins And Dividend Outlook Will Support Future Upside

Analysts have maintained their SEK 187.50 price target on AddLife, with updated assumptions around discount rate, revenue growth, profit margin and future P/E that now reflect a slightly different balance of risk, earnings potential and valuation multiples. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.50 per share, with ex date on May 7, 2026, record date on May 8, 2026, and payment on May 13, 2026 (Key Developments).
BIOA B
SEK 317.80
BioArctic
7D
-7.0%
1Y
79.3%

BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook

The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.
XVIVO
SEK 305.20
Xvivo Perfusion
7D
9.0%
1Y
10.6%

XVIVO: Stable Return Assumptions And Margins Will Support Balanced Future Outlook

Analysts have maintained their SEK245.0 price target for Xvivo Perfusion, citing slightly revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio, which together support a stable valuation view. Valuation Changes Fair Value: SEK245 has been reaffirmed, with only a minor presentational change from SEK245 to SEK245.0. Discount Rate: Adjusted slightly higher from 5.95% to 6.01%, reflecting a modest change in the required return assumption.
MCOV B
SEK 201.00
Medicover
7D
1.5%
1Y
-4.3%

MCOV B: Dividend Growth And 2028 Revenue Ambitions Will Support Upside

Analysts have nudged their Medicover price target higher to SEK227.29 from SEK225.05, citing updated assumptions that reflect a slightly higher discount rate, along with revised expectations for revenue growth, profit margins and future P/E. What's in the News The board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
MVIR
SEK 1.93
Medivir
7D
-18.2%
1Y
12.6%

Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects

Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
SANION
SEK 14.56
Saniona
7D
-6.3%
1Y
117.3%